Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review

被引:4
|
作者
Nies, Jasper F. F. [1 ]
Schneider, Udo [2 ]
Krusche, Martin [3 ]
机构
[1] Univ Med Ctr Cologne, Internal Med 2, Cologne, Germany
[2] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Nephrol Rheumatol & Endocrinol, Hamburg, Germany
关键词
adult-onset Still's disease (AOSD); interstitial lung disease; pulmonary arterial hypertension; IL-6; blocking; IL-1; PULMONARY ARTERIAL-HYPERTENSION; JUVENILE IDIOPATHIC ARTHRITIS; CYTOKINE; PATIENT; CELLS; MANIFESTATIONS; EPIDEMIOLOGY; PATHOGENESIS; SAFETY; IL-1;
D O I
10.3389/fmed.2022.989777
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adult-onset Still's disease (AOSD) is a polygenic systemic autoinflammatory disease which is associated with increased morbidity and mortality. Pulmonary involvement is a rare, but serious complication of AOSD. As in AOSD, IL-1b, IL-18, and IL-6 dominate the molecular pathogenesis, which mediate a type 1 and type 3 inflammatory signature of the adaptive immune system. This is evidenced by the success of IL-1- and IL-6 inhibition in the management of AOSD. However, anaphylactic reactions to treatment with IL-1- or IL-6-inhibitors is currently being discussed as a potential trigger for lung involvement inf AOSD, while genetic risk factors have also been identified. Clinically, pulmonary involvement in AOSD can manifest in many different forms. Parenchymal inflammation with peripheral consolidations is the most frequent form while PAH is less common, but often very difficult to manage. This mini-review provides an overview of the pathophysiology as well as the clinical presentation and the diagnostic features of pulmonary involvement in AOSD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Activation mechanisms of monocytes/macrophages in adult-onset Still disease
    Tsuboi, Hiroto
    Segawa, Seiji
    Yagishita, Mizuki
    Toko, Hirofumi
    Honda, Fumika
    Kitada, Ayako
    Miki, Haruka
    Ohyama, Ayako
    Hagiwara, Shinya
    Kondo, Yuya
    Matsumoto, Isao
    Sumida, Takayuki
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Myocarditis in Adult-Onset Still's Disease: Case-Based Review
    Gracia-Ramos, Abraham Edgar
    Contreras-Ortiz, Joshua Antonio
    CLINICAL RHEUMATOLOGY, 2020, 39 (03) : 933 - 947
  • [23] Tocilizumab for the treatment of adult-onset Still's disease
    Castaneda, Santos
    Martinez-Quintanilla, Dolores
    Martin-Varillas, Jose L.
    Garcia-Castaneda, Noelia
    Atienza-Mateo, Belen
    Gonzalez-Gay, Miguel A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (04) : 273 - 286
  • [24] Current and emerging biological therapy in adult-onset Still's disease
    Ma, Yuning
    Meng, Jianfen
    Jia, Jinchao
    Wang, Mengyan
    Teng, Jialin
    Zhu, Dehao
    Yang, Chengde
    Hu, Qiongyi
    RHEUMATOLOGY, 2021, 60 (09) : 3986 - 4000
  • [25] Efficacy of abatacept in a refractory case of adult-onset Still's disease
    Quartuccio, L.
    Maset, M.
    De Vita, S.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 265 - 267
  • [26] Renal manifestations in adult-onset Still's disease: a systematic review
    Arya, P. V. Akhila
    Marnet, Erica
    Rondla, Madhumita
    Tan, Jia Wei
    Unnikrishnan, Dileep
    Buller, Gregory
    RHEUMATOLOGY INTERNATIONAL, 2024, 44 (07) : 1209 - 1218
  • [27] Recent advances in the treatment of adult-onset Still's disease
    Chen, Der-Yuan
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (02): : 103 - 113
  • [28] Biological agents in the management of adult-onset Still's disease
    Girard-Guyonvarc'h, Charlotte
    Gabay, Cem
    JOINT BONE SPINE, 2019, 86 (01) : 5 - 7
  • [29] Coexistence of adult-onset Still's disease and SAPHO syndrome
    Wang, Yunuo
    Jiang, Haixu
    Yu, Xinbo
    Peng, Qiuwei
    Zheng, Zixiang
    Wu, Yuanhao
    Li, Chen
    ARCHIVES OF MEDICAL SCIENCE, 2024, 20 (03) : 1053 - 1056
  • [30] Interluekin-6 inhibitors for the treatment of adult-onset Still's disease
    Kaneko, Yuko
    MODERN RHEUMATOLOGY, 2022, 32 (01) : 12 - 15